It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The immunological features that distinguish COVID-19-associated acute respiratory distress syndrome (ARDS) from other causes of ARDS are incompletely understood. Here, we report the results of comparative lower respiratory tract transcriptional profiling of tracheal aspirate from 52 critically ill patients with ARDS from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a “cytokine storm,” we observe reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS is characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity. In silico analysis of gene expression identifies several candidate drugs that may modulate gene expression in COVID-19 ARDS, including dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 is characterized by impaired interferon-stimulated gene (ISG) expression. The relationship between SARS-CoV-2 viral load and expression of ISGs is decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients reveals distinct immunological features of COVID-19 ARDS.
Here, the authors perform transcriptional profiling on tracheal aspirates of adults requiring mechanical ventilation for SARS-CoV2-induced acute respiratory distress syndrome (ARDS) and identify a dysregulated host response predicted to predicted to be potentially modulated by dexamethasone.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a)
3 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a); University of California, Division of Infectious Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
4 University of California, Division of Infectious Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Division of Infectious Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
6 University of California, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
7 Washington University, Department of Anesthesia, Saint Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
8 University of California, Department of Microbiology and Immunology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Sandler Asthma Basic Research Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
9 Stanford University, Department of Emergency Medicine, Palo Alto, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
10 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of Toronto, Interdepartmental Division of Critical Care Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of California, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
11 University of California, School of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
12 University of California, Division of Rheumatology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
13 Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a); University of California, Department of Biochemistry and Biophysics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
14 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Anesthesia, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
15 University of California, Division of Hospital Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
16 University of California, Department of Pathology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Data Science CoLab, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Bakar ImmunoX Initiative, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
17 Zuckerberg San Francisco General Hospital and Trauma Center, Department of Nursing, San Francisco, USA (GRID:grid.416732.5) (ISNI:0000 0001 2348 2960)
18 University of California, Biospecimen Resource Program, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
19 University of California, Department of Microbiology and Immunology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
20 University of California, Department of Pathology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Bakar ImmunoX Initiative, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Anatomy, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Disease 2 Biology CoLab, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
21 Genentech Inc, Microchemistry, Proteomics and Lipidomics Department, South San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
22 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Lung Biology Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, CoLabs, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
23 University of California, Division of Rheumatology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Bakar ImmunoX Initiative, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, CoLabs, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
24 Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a); University of California, Department of Microbiology and Immunology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Otolaryngology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); Parker Institute for Cancer Immunotherapy, San Francisco, USA (GRID:grid.489192.f)
25 University of California, Department of Pathology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
26 University of California, Department of Orofacial Sciences, School of Dentistry, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
27 University of California, Core Immunology Laboratory, Division of Experimental Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
28 University of California, ImmunoX Initiative, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Departments of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Laboratory Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
29 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
30 University of California San Francisco, Division of Nephrology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Division of Critical Care Medicine, Department of Anesthesia, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
31 University of California, Department of Dermatology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
32 University of California, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
33 University of California, Helen Diller Family Comprehensive Cancer Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
34 University of California, Bakar ImmunoX Initiative, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Disease 2 Biology CoLab, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Biomedical Sciences Graduate Program, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
35 Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, USA (GRID:grid.416732.5) (ISNI:0000 0001 2348 2960)
36 University of California, Data Science CoLab, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Bakar ImmunoX Initiative, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, CoLabs, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
37 University of California, Department of Biochemistry and Biophysics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
38 University of California, Department of Nursing, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
39 University of California, Weill Institute for Neurosciences, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
40 University of California, School of Dentistry, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
41 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Sandler Asthma Basic Research Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
42 Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a); University of California, Division of Rheumatology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); Parker Institute for Cancer Immunotherapy, San Francisco, USA (GRID:grid.489192.f); University of California, Institute for Human Genetics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Epidemiology and Biostatistics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Institute of Computational Health Sciences, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
43 University of California, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Lung Biology Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, UCSF CoLabs, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
44 Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a); University of California, Division of Infectious Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)